KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Net Cash Flow: 2010-2025

Historic Net Cash Flow for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $357.8 million.

  • Halozyme Therapeutics' Net Cash Flow rose 1166.61% to $357.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.3 million, marking a year-over-year increase of 321.29%. This contributed to the annual value of -$2.5 million for FY2024, which is 97.83% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Net Cash Flow stood at $357.8 million, which was up 412.58% from -$114.5 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Net Cash Flow peaked at $357.8 million during Q3 2025, and registered a low of -$373.0 million during Q4 2021.
  • Its 3-year average for Net Cash Flow is $16.8 million, with a median of $23.2 million in 2024.
  • In the last 5 years, Halozyme Therapeutics' Net Cash Flow spiked by 2,390.17% in 2021 and then tumbled by 15,489.59% in 2023.
  • Halozyme Therapeutics' Net Cash Flow (Quarterly) stood at -$373.0 million in 2021, then spiked by 123.34% to $87.0 million in 2022, then plummeted by 279.07% to -$155.9 million in 2023, then spiked by 75.32% to -$38.5 million in 2024, then spiked by 1,166.61% to $357.8 million in 2025.
  • Its last three reported values are $357.8 million in Q3 2025, -$114.5 million for Q2 2025, and $60.5 million during Q1 2025.